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ABSTRACT
Objective: To assess the mediation of smoking-
associated postoperative mortality by postoperative
complications.
Design: Observational cohort study.
Setting: Using data from the Veterans Affairs (VA)
Surgical Quality Improvement Programme, a quality
assurance programme for major surgical procedures in
the VA healthcare system, we assessed the association
of current smoking at the time of the surgery with
6-month and 1-year mortality.
Primary and secondary outcome measures:
Using mediation analyses, we calculated the relative
contribution of each smoking-associated complication
to smoking-associated postoperative mortality, both
unadjusted and adjusted for age, race/ethnicity, work
relative value unit of the operation, surgeon specialty,
American Society of Anesthesiologists class and year
of surgery. Smoking-associated complications included
surgical site infection (SSI), cardiovascular
complications (myocardial infarction, cardiac arrest
and/or stroke) and pulmonary complications
(pneumonia, failure to wean and/or reintubation).
Results: There were 186 632 never smokers and
135 741 current smokers. The association of smoking
and mortality was mediated by smoking-related
complications with varying effects. In unadjusted
analyses, the proportions of mediation of smoking to
6-month mortality explained by the complications were
as follows: SSIs 22%, cardiovascular complications
12% and pulmonary complications 89%. In adjusted
analyses, the per cents mediated by each complication
were as follows: SSIs 2%, cardiovascular
complications 4% and pulmonary complications 22%.
In adjusted analyses for 1-year mortality, respective per
cents mediated were 2%, 3% and 16%.
Conclusions: Pulmonary complications, followed by
cardiovascular complications and SSIs were mediators
of smoking-associated 6-month and 1-year mortality.
Interventions targeting smoking cessation and
prevention and early treatment of pulmonary
complications has the likelihood of reducing
postoperative mortality after elective surgery.
INTRODUCTION
Smoking is the leading cause of preventable
death in the USA.1 2 While the prevalence of
smoking in the USA has decreased,3 smoking
is still highly prevalent with a recent national
ARTICLE SUMMARY
Article focus
▪ We aimed to examine whether smoking-associated
postoperative mortality is mediated through
smoking-associated postoperative complications in
patients who were current smokers at the time of
their surgery.
▪ We hypothesised that specific smoking-associated
complications (surgical site infections (SSIs), pul-
monary and cardiovascular) in the postoperative
period in current smokers, mediate smoking-related
6-month and 1-year mortality.
Key messages
▪ Pulmonary complications, followed by cardiovas-
cular complications and SSIs were mediators of
smoking-associated 6-month and 1-year mortal-
ity after elective knee or hip replacement surgery.
▪ Preoperative smoking counselling and implemen-
tation of smoking cessation programmes should
be performed prior to an elective surgery such
as knee/hip replacement.
▪ Early treatment of complications that mediate
postoperative 1-year mortality may help reduce
risk of dying after an elective surgery.
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survey showing between 10% and 26% prevalence in
most of the US states.4 The prevalence of smoking in
veterans using Veterans Affairs (VA) healthcare is even
higher, at 30%.5 Smoking has detrimental effects on car-
diovascular and lung health, and is linked to increased
risk of surgical complications. Speciﬁcally, smokers
undergoing surgery have a higher risk of several post-
operative complications including wound infections,
pneumonia and mortality.6 7 Smoking is a modiﬁable
risk factor.8–10 Preoperative smoking cessation is asso-
ciated with decreased postoperative wound complica-
tions and total complications.11
While smoking-related postoperative morbidity is
important, smoking is also associated with increased
postoperative mortality.12–14 There are several proposed
mechanisms of increased mortality in the perioperative
period for smokers including higher risk of cardiac13 14
and pulmonary complications.12 To our knowledge, no
previous studies have assessed to what degree the
increased smoking-associated postoperative mortality is
mediated by speciﬁc complications associated with
smoking. This has important consequences for design-
ing interventions to improve outcomes. If the effect of
smoking on mortality were direct (direct toxic effects on
health, low likelihood), then the only effective method
to improve smoking-related outcomes would be smoking
cessation. Alternatively, to the extent that smoking is
related to mortality through an increase in pulmonary
complications among smokers, the effect of smoking is
said to act through the mediating factor of pulmonary
complications. Such a result would suggest that interven-
tions to reduce pulmonary complications among
smokers may be an additional strategy for improving the
mortality outcome.
We have recently demonstrated that smoking was asso-
ciated with both postoperative surgical site infections
(SSIs) and pulmonary complications in a large cohort of
veterans who underwent surgery in VA medical facilities
and that mortality was also increased in this cohort.15
These data are collected prospectively and systematically
as part of the National VA Surgical Quality Improvement
Program (VASQIP).16 17
In this study, we aimed to examine whether
smoking-associated postoperative mortality is mediated
through smoking-associated postoperative complications
in patients who are current smokers at the time of their
surgery. Conceptually, ‘mediation’ occurs when a cause
and its effects are linked through an intervening factor
that is part of the causal chain of events.18 As an example,
this study explored the link between smoking and post-
operative morbidity and mortality. We hypothesised that
speciﬁc smoking-associated complications (SSI, pulmon-
ary and cardiovascular) in the postoperative period in
current smokers, mediate smoking-related 6-month and
1-year mortality. This was performed in two steps: we ﬁrst
established a link between smoking and adverse out-
comes, and we then investigated and quantiﬁed the pro-
portion of the observed association appearing to act
through a particular and plausible mediator, in this case,
smoking-associated complications.
METHODS
Ethical approval, study funding and data sharing
The study was approved by the Institutional Review
Boards at the VA Medical Centers (Birmingham,
Alabama, Bedford, Massachusetts, Boston, Massachusetts
and Seattle, Washington), the University of Colorado
and by the Surgical Quality Data Use Group of VA
Patient Care Services in VA Central Ofﬁce, Washington
DC (as needed for studies using data from this dataset).
All analyses used SAS V.9.2 (SAS Institute Inc, Cary,
North Carolina). This material is the result of work sup-
ported with VA Investigator-Initiated Research (IIR) IAB
06-038-2. Additionally, Dr Singh’s time was protected by
research grants from the National Institute of Aging,
National Cancer Institute and Agency for Health Quality
and Research Center for Education and Research on
Therapeutics (CERTs). The study authors are committed
to sharing the data with colleagues after an ethics com-
mittee approval and in accordance with VA data privacy
and data security rules.
Study sample
We used data from the VASQIP, a system-wide initiative
instituted in 1994 to improve the quality of surgical
care through prospective collection and reporting of
comparative risk-adjusted postoperative outcomes of
major surgeries requiring general, spinal or epidural
anesthesia.19 The abstracted data are >99% complete
with >96% interobserver agreement.17 We requested
all cases in major procedure groups deﬁned by common
procedural terminology codes within each of the eight
surgical subspecialties (general, vascular, orthopaedic,
thoracic, otolaryngology, urology, neurosurgery and
ARTICLE SUMMARY
Strengths and limitations of this study
▪ Use of prospectively collected national data in the largest inte-
grated healthcare system in the USA.
▪ Outcomes and complications had been defined using standar-
dised definitions and validated by nurse abstractors.
▪ Findings may not be generalisable to women and non-veteran
US population, since our sample included primarily men, rep-
resentative of US veterans.
▪ The current smoker variable is collected retrospectively from
medical records, which could lead to misclassification bias
and underestimation of the association.
▪ Smoking status may change over time and the current study
could not take that into account, since ongoing smoking
status data are not available.
▪ Mediation assumes no unmeasured variables and despite
accounting for all the important variables to the best of our cap-
ability with the given data, residual confounding is possible.
2 Singh JA, Hawn M, Campagna EJ, et al. BMJ Open 2013;3:e002157. doi:10.1136/bmjopen-2012-002157
Mediators of mortality in smokers undergoing arthroplasty
 group.bmj.com on April 15, 2014 - Published by bmjopen.bmj.comDownloaded from 
plastic surgery) for the years 2002–2008. This produced
a sample of roughly 60–70% of all non-cardiac opera-
tions in the VASQIP database for those years
(n=507 545). We selected the ﬁrst operation for each
patient greater than or equal to 19 years of age, resulting
in 412 511 unique patients. We excluded 17 202 patients
coded as having emergency operations, since we wanted
to focus on elective surgeries. We also excluded 1 515
patients who were coded as a current smoker but who
had 0 pack-years (an inconsistency) or were missing the
current smoker variable. Since our focus was current
smoking, we excluded 71 421 prior smokers leaving a
total of 322 373 patients for analysis.
Independent measure: current smoking
Smoking status was assessed using two variables. Patients
are queried at the time of elective surgery if they have
smoked cigarettes in the year prior to admission
(yes/no) and regarding amount of smoking (pack-
years=the number of packs smoked per day multiplied
by the number of years the patient smoked), documen-
ted in patients’ medical records. Never smokers were
patients who had no smoking in the prior year and zero
(or missing) pack-years. Current smokers were those
who responded ‘yes’ to smoking in the year prior to
admission and had pack-years not equal to zero.
Dependent measure: mortality
Mortality was assessed at 6 months and at 1 year. The
VASQIP nurses have collected a 30-day postoperative
vital status for all the patients assessed in the VASQIP
program. Once every 6 months, the VASQIP database is
passed through the VA administrative vitals ﬁle to obtain
data on long-term postoperative mortality beyond
30 days after surgery.
Mediation variables: 30-day outcomes for complications
All complications of interest were assessed 30 days after
elective surgery. Speciﬁcally, the outcomes included: (1)
SSIs; (2) cardiovascular complications, deﬁned as occur-
rence of myocardial infarction, cardiac arrest and/or
stroke; (3) pulmonary complications, deﬁned as occur-
rence of pneumonia, failure to wean and/or reintuba-
tion and (4) overall composite outcome, deﬁned as the
occurrence of SSI, cardiovascular and/or pulmonary
complications. All outcomes have standard deﬁnitions in
VASQIP and are extracted and validated for each patient
by an independent nurse abstractor at each VA site for
the 30-day period after the surgery.16 17
Covariates: patient, surgeon and procedural
characteristics
Patient characteristics including age, race/ethnicity,
American Society of Anesthesiologists (ASA) class, year
of surgery, work relative value unit (RVU) for the oper-
ation and wound classiﬁcation were extracted. ASA class
is a validated measure of perioperative mortality and
immediate postoperative morbidity, categorised into ﬁve
classiﬁcations20 21 (class I, normal healthy patient;
class II, patient with mild systemic disease (with no func-
tional limitation); class III, patient with severe systemic
disease (with some functional limitation); class IV,
patient with severe systemic disease that is a constant
threat to life; class V, moribund patient). Work RVU
(a measure of procedure duration and complexity) and
surgeon subspecialty were collected by chart review.
These variables were chosen based on previous literature
of association of these factors with mortality or because
they represented the complexity of the surgery.
Statistical analyses
Summary statistics were calculated for clinical and demo-
graphic characteristics. Mediation analysis was performed
with and without controlling for covariates that could
potentially confound the relationship. Univariable and
multivariable-adjusted logistic regression analyses were
used to compute coefﬁcients for association of smoking
and mortality, smoking and major complications (SSI,
pulmonary, cardiovascular or composite) and major com-
plications and mortality, to assess mediation effect of
complications on the relationship between smoking and
mortality. In multivariable analyses, we adjusted for age,
race/ethnicity, work RVU, surgeon specialty, ASA class
and year at each step of the mediation analysis. Wound
classiﬁcation was additionally adjusted for in the model
when assessing the mediation effect of SSI.
The conceptual framework of ‘mediation’ indicates
that mediation occurs when a cause and its effect are
linked through an intervening factor that is part of the
causal chain of events.18 The classic exposition of statis-
tical mediation analysis was given by Baron and Kenny.18
The mediating relationship was conceived in causal
terms, so while it was recognised that the statistical
models cannot establish causality, the causal interpret-
ation of the posited relationships must be plausible. The
precondition was that the independent variable
(smoking) is statistically signiﬁcantly associated with the
dependent variable (eg, 6-month mortality). The total
effect of smoking on mortality was denoted by the path
‘c’ in ﬁgure 1 representing the association of smoking
on mortality without adjustment for the potential medi-
ator. Baron and Kenny outlined three steps for a formal
mediation analysis using regression, which can be
explained with reference to ﬁgure 1 in the context of
the relationship between smoking and 6-month mortal-
ity with the putative mediating effect of pulmonary com-
plications. The ﬁrst step was to establish that there is a
signiﬁcant association between the independent variable
(smoking) and the potential mediator (pulmonary com-
plications) corresponding to the path coefﬁcient ‘a’ in
ﬁgure 1. The second step was to establish that the poten-
tial mediator (pulmonary complications) is associated
with the dependent variable (6-month mortality), while
controlling for the independent variable (smoking), cor-
responding to the path coefﬁcient ‘b’. Last, when con-
trolling for the mediator (pulmonary complications) the
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‘direct effect’ of the independent variable (smoking) on
the dependent variable (6-month mortality) corresponds
to the coefﬁcient ‘c0’. We interpret the ‘direct effect’ to
be the ‘lifetime exposure’ of smoking. Less technically, if
(1) smoking was related to both pulmonary complica-
tions and mortality, (2) pulmonary complications were
related to mortality and (3) the magnitude of the rela-
tionship between smoking and mortality decreased by a
statistically signiﬁcant amount when controlling for pul-
monary complications, then there was a signiﬁcant
amount of mediation by pulmonary complications.
Arithmetically, the indirect effect is equal to the product
of coefﬁcients a×b while the total effect (c) is equal to the
indirect effect (a×b) plus the remaining direct effect (c0),
thus: c=a×b+c0, so c0=c−a×b. Clearly, as the indirect effect
through the mediator gets larger, the residual direct effect
must decrease, implying that a larger part of the effect is
via the mediator. The more the direct effect is diminished,
the greater part of the effect is mediated.
The statistical signiﬁcance of the mediated, or indirect,
effect was determined by testing whether the product a×b
is statistically different from zero. The standard approxi-
mate test was due to the work of Sobel, and presented by
Baron and Kenny.18 Subsequent work, notably by Shrout
and Bolger22 note that the Sobel test can be overly con-
servative for small samples but also that this ceases to be a
concern when the sample size is greater than 1 000. The
much larger sample size of this study suggested that the
Sobel test was adequate in this context.
To evaluate the importance of the mediation it can
be informative to calculate the proportion of the effect
owing to mediation as the indirect effect divided by the
total effect as a×b/c. In our work, the independent,
dependent and mediator variable were all dichotomous.
In this context where logistic regression is used a×b+c0
may only approximate c, so we followed the methods of
MacKinnon and Dwyer23 and calculated the proportion
of the effect owing to mediation using coefﬁcients stan-
dardised to the same scale. We present only the unstan-
dardised coefﬁcients because they are more
interpretable within the context of the individual
regression models.
RESULTS
There were 186 632 never smokers and 135 741 current
smokers. The mean age was 63 years for never smokers
and 58 years for current smokers. In total, 95% were
men and 63% were Whites (race/ethnicity missing in
19%; table 1). Diabetes was less common among current
smokers compared with never smokers, but chronic
obstructive pulmonary disease (COPD), dyspnoea and
alcohol consumption were more common. Other char-
acteristics were similar between the two groups (table 1).
Crude estimates of outcomes by smoking status are
shown in table 2.
Mediation analyses for 6-month and 1-year mortality
Unstandardised coefﬁcients were calculated without
(unadjusted; table 3) and with (adjusted; table 4) poten-
tial confounders using regression analyses. Variances for
computing standardised coefﬁcients are footnoted. The
unadjusted coefﬁcients were highest between smoking
and pulmonary complications (coefﬁcient a=0.46), and
between pulmonary complications and 6-month mortal-
ity, controlling for smoking was (coefﬁcient b=2.90)
among all complications (table 3); similar observations
were made for pulmonary complications and 1-year mor-
tality. In general, unadjusted coefﬁcients were higher
than adjusted coefﬁcients.
Table 4 provides coefﬁcients for the mediation ana-
lyses controlling for confounding from age, race/ethni-
city, work RVU, surgeon specialty, ASA class and year for
6-month and 1-year mortality. Mediation analysis for SSI
additionally controlled for wound classiﬁcation. The
coefﬁcients for the path from smoking to 6-month and
12-month mortality while considering the mediation
factor of SSI were 0.39 and 0.45 (coefﬁcient c). Again, as
an example, the coefﬁcient between smoking and pul-
monary complications was 0.48 (coefﬁcient a), between
pulmonary complications and 6-month mortality con-
trolling for smoking was 2.17 (coefﬁcient b), and that
between smoking and 6-month mortality controlling
for pulmonary complications was 0.32 (coefﬁcient c0).
The association between smoking and 6-month
mortality was signiﬁcantly mediated by pulmonary com-
plications (22%; table 5). For 6-month mortality,
adjusted coefﬁcients between smoking and complica-
tions were highest for pulmonary complications (0.48),
followed by composite outcome (0.29), SSI (0.19) and
cardiovascular complications (0.19; coefﬁcient a).
Adjusted coefﬁcients were highest for pulmonary fol-
lowed by cardiovascular, composite and SSI complications
for association with 6-month mortality, controlling for
Figure 1 Path diagram of the relations among the three
standardised variables and standardised coefficients of paths.
a=regression coefficient for path from smoking to pulmonary
complications; b=regression coefficient for path from
pulmonary complications to 6-month mortality, controlling for
smoking; c0=regression coefficient for path from smoking to
6-month mortality, controlling for pulmonary complications;
c=regression coefficient for direct path from smoking to
6-month mortality. Smoking is the independent variable,
pulmonary complications the mediator and 6-month mortality
dependent variable. a, b, c and c0 are coefficients from logistic
regression analyses.
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smoking (coefﬁcient b). The proportion of mediation of
smoking to 6-month mortality explained by the complica-
tions in adjusted analyses was 16% for the composite
outcome, while the proportions were lower for SSI (2%)
and cardiovascular complications (4%; table 5).
Similar patterns were noted for mediation of smoking
and 1-year mortality for adjusted coefﬁcients (table 4).
In the adjusted models, the proportion of mediation of
smoking to 1-year mortality explained by the complica-
tions in adjusted analyses was 16% for pulmonary com-
plications, 11% for composite complications, 3% for
cardiovascular complications and 2% for SSI (table 5).
Table 1 Patient characteristics by smoking status*
(column per cents unless noted otherwise)
Characteristic
Never
smoked
(n=186 632)
Current
smoker
(n=135 741)
Smoking pack-years,
mean (SD)
N/A 48.8 (32.6)
Demographics
Age, mean (SD) 63.1 (13.7) 57.6 (11.0)
Sex (%)
Female 5.1 4.1
Male 94.9 95.9
Race/ethnicity (%)
White 62.3 63.1
Black 12.3 14.9
Hispanic 5.3 2.7
Other/unknown 20.2 19.3
Comorbidities (%)
Diabetes 20.2 14.6
Congestive heart failure 1.2 1.0
History of severe COPD 7.0 18.4
Dyspnoea 8.4 15.4
Chronic corticosteroid use 1.7 1.7
Renal failure/dialysis 0.7 0.5
CVA/stroke 5.9 6.6
Transient ischaemic attacks 2.9 3.6
Functional health status (%)
Independent 93.5 94.8
Partially dependent 5.2 4.6
Totally dependent 1.3 0.6
>10% loss body weight in
past 6 months
1.8 3.4
Disseminated cancer 1.0 1.3
Open wound/wound
infection
3.2 4.3
DNR status 0.9 0.6
Alcohol >2 drinks/day 4.3 14.6
Operative characteristics
Anaesthesia technique (%)
General 79.4 84.8
Epidural/spinal 15.6 10.9
Local/monitored 5.1 4.2
ASA classification (%)
1 4.4 1.6
2 35.8 33.4
3 53.8 58.2
4/5 6.1 6.8
Admission status (%)
Outpatient 51.0 47.1
Inpatient 49.0 52.9
Specialty of surgeon (%)
General surgery 39.3 35.3
Neurosurgery 5.4 7.9
Orthopaedic surgery 29.6 21.9
Otolaryngology 1.1 1.3
Plastic surgery 0.6 0.6
Thoracic surgery 1.7 5.6
Continued
Table 1 Continued
Characteristic
Never
smoked
(n=186 632)
Current
smoker
(n=135 741)
Urology 15.6 13.1
Cardiovascular surgery 6.3 13.8
Other 0.4 0.4
Wound classification (%)
Clean 70.0 70.8
Clean/contaminated 27.3 26.2
Contaminated 1.6 1.6
Infected 1.2 1.4
Work RVU (mean, SD) 14.1 (7.1) 14.8 (7.8)
Operation time, hours
(mean, SD)
1.9 (1.4) 2.1 (1.6)
*All p value are <0.001 with the exception of steroid use, for which
was 0.581.
ASA, American Society of Anesthesiologists; COPD, chronic
obstructive pulmonary disease; CVA, cerebrovascular accident;
DNR, Do not resuscitate; N/A, not applicable; RUV, relative value
units.
Table 2 Frequency of outcomes by smoking status
Postoperative outcome
Never
smoked
(n=186632)
Current
smoker
(n=135741)
Surgical site infection 2.4 3.4
Vascular complications 0.5 0.5
Cerebral vascular
accident/stroke
0.2 0.3
Myocardial infarction 0.3 0.3
Pulmonary complications 2.0 3.1
Reintubation for respiratory
or cardiac failure
0.9 1.6
Pneumonia 1.2 1.9
Failure to wean >48 h 0.8 1.4
Composite outcome 4.5 6.5
Death within 6 months* 3.5 3.9
Death within 1 year* 5.3 6.4
Results presented as column percentage.
*Never, N=186305; current, N=135561.
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DISCUSSION
In this analysis of prospectively collected data in a
national sample of non-cardiac elective surgeries at VA
facilities, we found that increased 6-month and 1-year
smoking-associated mortalities were mediated by
pulmonary complications and to a lesser extent cardio-
vascular complications and SSIs. Not unexpectedly, esti-
mates of the proportion of smoking-related mortality
mediated by each perioperative complications were all
numerically larger for 6-month mortality compared with
Table 3 Unadjusted coefficients* and their 95% CIs
Outcome Mediator c 95% CI a 95% CI b 95% CI c0 95% CI
6 months
mortality†
SSIs 0.12 0.08 to 0.15 0.37 0.33 to 0.41 0.89 0.81 to 0.96 0.10 0.07 to 0.14
Cardiovascular complications 0.12 0.08 to 0.15 0.15 0.05 to 0.24 2.70 2.60 to 2.80 0.11 0.07 to 0.15
Pulmonary complications 0.12 0.08 to 0.15 0.46 0.42 to 0.51 2.90 2.85 to 2.95 0.01 −0.02 to 0.05
Composite outcome 0.12 0.08 to 0.15 0.39 0.36 to 0.42 2.21 2.17 to 2.25 0.02 −0.02 to 0.05
1 year
mortality‡
SSIs 0.20 0.17 to 0.23 0.37 0.33 to 0.41 0.83 0.76 to 0.89 0.19 0.16 to 0.22
Cardiovascular complications 0.20 0.17 to 0.23 0.15 0.05 to 0.24 2.42 2.32 to 2.52 0.20 0.17 to 0.23
Pulmonary complications 0.20 0.17 to 0.23 0.46 0.42 to 0.51 2.60 2.57 to 2.64 0.13 0.10 to 0.17
Composite outcome 0.20 0.17 to 0.23 0.39 0.36 to 0.42 1.91 1.88 to 1.95 0.13 0.10 to 0.16
c=direct path from smoking to mortality.
a=path from smoking to complications (SSI, cardiovascular, pulmonary or composite).
b=path from complications (SSI, etc) to mortality controlling for smoking.
c0=path from smoking to mortality controlling for complications (SSI, etc).
*All coefficients were unstandardised and rounded off to two digits after the decimal.
†Variances used to compute standardised coefficients22: var (smoking)=0.975, var (mortality)=0.036, var (predicted mortality|smoking0)=3.30,
var (SSI)=0.028, var (predicted SSI|smoking’)=3.42, var (predicted mortality|smoking and SSI00)=3.32, var (cardiovascular)=0.005, var
(predicted cardiovascular|smoking0)=3.31, var (predicted mortality|smoking and cardiovascular00)=3.34, var (pulmonary)=0.024, var (predicted
pulmonary|smoking0)=3.50, var (predicted mortality|smoking and pulmonary00)=3.49, var (composite)=0.051, var (predicted composite|
smoking0)=3.44, var (predicted mortality|smoking and composite00)=3.54.
‡Variances used to compute standardised coefficients22: var (smoking)=0.975, var (mortality)=0.054, var (predicted mortality|smoking0)=3.33,
var (SSI)=0.028, var (predicted SSI|smoking0)=3.42, var (predicted mortality|smoking and SSI00)=3.34, var (cardiovascular)=0.005, var
(predicted cardiovascular|smoking0)=3.31, var (predicted mortality|smoking and cardiovascular00)=3.36, var (pulmonary)=0.024, var (predicted
pulmonary|smoking0)=3.50, var (predicted mortality|smoking and pulmonary00)=3.47, var (composite)=0.051, var (predicted composite|
smoking0)=3.44, var (predicted mortality|smoking and composite00)=3.49.
SSIs, surgical site infections; var, variance.
Table 4 Adjusted coefficients* and their 95% CIs controlling for confounding
Outcome Mediator c 95% CI a 95% CI b 95% CI c0 95% CI
6 months
mortality†
SSIs 0.39 0.35 to 0.44 0.19 0.14 to 0.24 0.45 0.37 to 0.53 0.39 0.35 to 0.43
Cardiovascular complications 0.38 0.34 to 0.42 0.19 0.08 to 0.30 2.00 1.89 to 2.12 0.38 0.34 to 0.42
Pulmonary complications 0.38 0.34 to 0.42 0.48 0.43 to 0.54 2.17 2.11 to 2.23 0.32 0.27 to 0.36
Composite outcome 0.38 0.34 to 0.42 0.29 0.25 to 0.32 1.71 1.66 to 1.76 0.33 0.28 to 0.37
1 year
mortality‡
SSIs 0.45 0.42 to 0.49 0.19 0.14 to 0.24 0.44 0.37 to 0.51 0.45 0.41 to 0.48
Cardiovascular complications 0.44 0.40 to 0.47 0.19 0.08 to 0.30 1.77 1.66 to 1.88 0.44 0.40 to 0.47
Pulmonary complications 0.44 0.40 to 0.47 0.48 0.43 to 0.54 1.90 1.85 to 1.96 0.39 0.36 to 0.43
Composite outcome 0.44 0.40 to 0.47 0.29 0.25 to 0.32 1.44 1.40 to 1.48 0.40 0.36 to 0.44
c=direct path from smoking to mortality controlling for age, race/ethnicity, work RVU, surgeon specialty, ASA class and year.
a=path from smoking to complications (SSI, cardiovascular, pulmonary or composite) controlling for age, race/ethnicity, work RVU, surgeon
specialty, ASA class and year.
b=path from complications (SSI, etc) to mortality controlling for smoking, age, race/ethnicity, work RVU, surgeon specialty, ASA class
and year.
c0=path from smoking to mortality controlling for complications (SSI, etc), age, race/ethnicity, work RVU, surgeon specialty, ASA class
and year.
*All coefficients were unstandardised and were rounded off to two digits after the decimal.
†Variances used to compute standardised coefficients22: var (smoking)=0.975, var (mortality)=0.036, var (predicted mortality|smoking
[SSI)0)=3.44, var (predicted mortality|smoking (cardiovascular, pulmonary and composite)0)=3.43, var (SSI)=0.028, var (predicted SSI|
smoking0)=3.32, var (predicted mortality|smoking and SSI00)=3.44, var (cardiovascular)=0.005, var (predicted cardiovascular|smoking0)=3.33,
var (predicted mortality|smoking and cardiovascular00)=3.45, var (pulmonary)=0.024, var (predicted pulmonary|smoking0)=3.52, var (predicted
mortality|smoking and pulmonary00)=3.49, var (composite)=0.051, var (predicted composite|smoking0)=3.37, var (predicted mortality|smoking
and composite00)=3.53.
‡Variances used to compute standardised coefficients22: var (smoking)=0.975, var (mortality)=0.054, var (predicted mortality|smoking
(SSI)0)=3.49, var (predicted mortality|smoking (Cardiovascular, pulmonary and Composite)0)=3.48, var (SSI)=0.028, var (predicted SSI|
smoking0)=3.32, var (predicted mortality|smoking and SSI00)=3.49, var (cardiovascular)=0.005, var (predicted cardiovascular|smoking0)=3.33,
var (predicted mortality|smoking and cardiovascular00)=3.49, var (pulmonary)=0.024, var (predicted pulmonary|smoking0)=3.52, var (predicted
mortality|smoking and pulmonary00)=3.52, var (composite)=0.051, var (predicted composite|smoking0)=3.37, var (predicted mortality|smoking
and composite00)=3.54.
ASA, American Society of Anesthesiologists; RVU, relative value unit; SSIs, surgical site infections; var, variance.
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that for 1-year mortality, although this was not tested stat-
istically. The proportion mediated by complications also
attenuated signiﬁcantly between adjusted and
unadjusted analyses, as expected. These observations are
novel and have important implications for targeting
interventions for patients undergoing elective surgery.
That smoking is associated with increased mortality
after elective surgical procedures is well known.12 13
Preoperative period has been proposed a ‘window of
opportunity’ and a ‘teachable moment’ to help patients
quit smoking.24 25 This study examined a critical ques-
tion, that is, is this increased mortality mediated by the
postoperative complications seen more commonly in
smokers than in non-smokers? The evidence presented
here conﬁrmed that these postoperative complications
mediated signiﬁcant proportion of increased mortality
risk, and that this varied by the type of complication.
Pulmonary complications explained the most variation
in this increased risk, as compared with cardiovascular
complications or SSIs. Our ﬁndings suggest pulmonary
complications are far more important contributors to the
smoking–mortality association than the cardiovascular
complications. There has been signiﬁcant emphasis
placed on preoperative cardiac risk assessment for non-
cardiac surgery.26 Consensus statements on cardiac risk
stratiﬁcation including who should undergo screening
and revascularisation and management of patients with
implanted cardiac stents have been developed and widely
disseminated.27–29 Perhaps this focus and attention on
identifying and intervening on cardiac risk has mitigated
the associations of smoking-related cardiovascular events
with mortality, in both smokers and never smokers.
Similar attention has not been given to preoperative risk
stratiﬁcation for postoperative pulmonary events. These
events occur more frequently than cardiovascular events
and lead to substantial postoperative mortality.30–35
Perioperative complications associated with smoking
mediated a high proportion of the association of
smoking and mortality before adjustment. But the pro-
portion mediation was greatly attenuated after adjust-
ment. This suggests that a major part of the mediation
effect was contained in variables we adjusted for includ-
ing ASA class. In addition, some of the association of
smoking and subsequent mortality is related to lifetime
exposure to smoking (direct effect), and not the associ-
ation of smoking on perioperative complications (indir-
ect effect through pulmonary complications). This may
be related to occurrence of major lifetime complications
from smoking, for example, COPD, coronary artery
disease, various cancers and stroke, which can all con-
tribute to postoperative mortality.
We did ﬁnd that even after adjustment, smoking-related
pulmonary complications mediated over 15% of the asso-
ciation of smoking and postoperative mortality. Thus,
part of the association of smoking on mortality is because
of a lifetime exposure, as shown previously,36 and part
owing to immediate complications, such as pulmonary
complications. The ﬁrst goal should always be to get
smokers to quit prior to surgery. But acknowledging that
not all smokers will quit prior to their surgery, the surgi-
cal staff should be especially vigilant of pulmonary com-
plications, as our data clearly demonstrates them to
mediate mortality. Careful monitoring of adherence to
pneumonia prevention guidelines in postoperative
period as well as early diagnosis and management may
lead to reduction in mortality. Far more importantly, pre-
ventive preoperative evaluation and optimisation of pul-
monary health in addition to implementation of
preoperative smoking cessation programmes in patients
undergoing elective surgery have the likelihood of redu-
cing the increased mortality risk. Consensus statements
on pulmonary risk assessment and patients who should
be referred for intervention are strongly needed.
We found that the attributable risk of SSI to
smoking-related mortality was lower than that for pul-
monary and cardiovascular complications. SSIs consti-
tute the most common infection, accounting for 38% of
all infections.6 In addition, SSIs are associated with sig-
niﬁcant increases in hospital stay,6 making them one of
the most costly postoperative complications.6 37 SSIs are
the third most common nosocomial infection overall,
representing 14% of all hospital-acquired infections.
Table 5 Proportion of mediation of smoking to mortality association explained by each complication in unadjusted and
adjusted models
Outcome Mediator
Proportion mediation
unadjusted for covariates (%)
Proportion mediation
adjusted for covariates (%)
6 months mortality Surgical site infection 22.2 2.0
Cardiovascular complications 12.2 3.8
Pulmonary complications 88.9 21.6
Composite outcome 86.4 15.7
1 year mortality Surgical site infection 12.6 1.7
Cardiovascular complications 6.5 3.0
Pulmonary complications 42.7 16.2
Composite outcome 40.8 11.3
Because the proportion mediated is ratio statistic, its estimated value is sensitive to variation in point estimates of the regression coefficients
from which it is derived; it should therefore be interpreted with caution. Coefficient values (magnitude and significance) should be the main
proponent in assessing mediation.
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Thus even though their contribution to mortality is
lower, their common prevalence and the ability to insti-
tute measures to prevent them make them suitable
targets for interventions.
The proportion mediated by each of the three compli-
cations was attenuated by adjustment for age, race/eth-
nicity, work RVU, surgeon specialty and ASA class,
indicating that these factors may have contributed to
mortality outcome. In addition, other factors that we did
not measure in this study such as other smoking-related
diseases such as cancer, COPD, etc may have contribu-
ted. Additionally, as is common in observational studies
such as this, smoking status may be a marker for
unmeasured variables that may be causal. Thus, smoking
status should alert clinicians to other factors, which may
need to be addressed preoperatively.
Our study has several limitations. It is possible that
ﬁndings may not be generalisable to women, since our
sample included primarily men, representative of US vet-
erans. These ﬁndings may not be generalisable to non-
veterans; however, it is unlikely that the pathway of
smoking-associated mortality risk differs by the veteran
status. The current smoker variable in VASQIP is col-
lected retrospectively from medical records, which could
lead to misclassiﬁcation bias and underestimation of the
association. Thus, these results are conservative estimates
of these associations. Another limitation is that smoking
status may change over time and the current study
design and analyses did not take that into account.
Mediation assumes no unmeasured variables; this is of
course not true as we can never account for all omitted
factors. We accounted for all the important variables to
the best of our capability with the given data. Another
limitation of the mediation analysis is that the propor-
tion mediated is inﬂuenced by sample size, coefﬁcient
estimates and distribution of the outcomes/predictors
and since our variables were dichotomous and we have
small standardised coefﬁcient estimates. Cause of death
was not available to us, so these details could not be pro-
vided for smokers and never smokers.
In conclusion, this study found that a high proportion
of association between smoking and postoperative
6-month and 1-year mortality is mediated by post-
operative complications, especially pulmonary complica-
tions. Future efforts at reducing postoperative mortality
should be aimed at preoperative risk identiﬁcation and
intervention. Efforts directed at pulmonary risk stratiﬁca-
tion, surveillance and prevention for pulmonary and
other complications in smokers undergoing elective
surgery may likely impact mortality in current smokers
undergoing elective surgical procedures.
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